Melanoma progression is typically depicted as a linear and stepwise process in which metastasis occurs relatively late in disease progression. Significant evidence suggests that in a subset of melanomas, progression is much more complex and less linear in nature. Epidemiologic and experimental observations in melanoma metastasis are reviewed here and are incorporated into a comprehensive model for melanoma metastasis, which takes into account the varied natural history of melanoma formation and progression.
INTRODUCTION
Melanoma rates are rising worldwide. 1 Most morbidity and mortality in melanoma is associated with metastatic disease, which can occur even from thin primary tumors. 2 Accordingly, metastasis is a particularly ominous sign; when metastasis is clinically evident, prognosis is very poor. For example, melanoma patients with three or more sites of metastatic disease die within 1 year 495% of the time. 3, 4 New targeted and immunomodulatory therapies such as vemurafenib and ipilimumab have offered the first improvements in overall survival to melanoma patients in several decades. 5, 6 Unfortunately, only a subset of patients benefit in a durable fashion from these therapies, while most will still ultimately succumb to metastatic disease.
Melanoma results from the malignant proliferation of melanocytes, the normal pigment producing cells in skin. Classically melanoma progression and metastasis has been depicted using the Clark model. 7 In this model, progression of normal melanocytes to metastatic melanoma is linear, and consists of a series of steps including: benign precursor lesion formation (melanocytic nevus), dysplastic nevus, progression through both radial and vertical growth phases of primary tumor growth, and ultimately metastasis ( Figure 1 ). The accumulation of genetic and epigenetic changes is thought to drive progression through these steps. 8 In the Clark model, metastasis ensues late in disease progression, only after all previous steps have been completed and relatively rare clones with metastatic competency emerge. Although this model likely depicts the natural history of some melanomas, several pathologic, epidemiologic, and experimental observations suggest that the progression of other melanomas may be more complex and less linear in nature. Evolving conceptual paradigms of melanoma progression that account for these additional observations and incorporate the many individual steps in metastasis will be explored here.
TEMPORAL AND SPATIAL COMPLEXITY OF METASTASIS
Metastasis involves a series of steps which must be completed before the emergence of clinically meaningful metastatic disease ( Figure 1 ). These steps are further complicated by additional observations from human melanoma patients which add temporal and spatial complexity to metastasis. Many melanoma patients are cured after excision of their primary tumor; however, some are not, and will have disease recurrence. Melanoma recurs less frequently at the site of the original primary tumor, instead more commonly recurring at different sites in the body as metastatic lesions. 9 These recurrence patterns suggest that melanoma cells had already spread before excision of the primary tumor, even though this spread might not have been clinically apparent at that time. In melanoma patients, metastatic recurrence can occur within a relatively short period of time, but takes 45 years in about 40% of patients. 4, [10] [11] [12] The period in between initial excision of the primary tumor and subsequent metastatic recurrence is often referred to as metastatic dormancy, where previously disseminated tumor cells are thought to persist in a relatively non-proliferative state.
The mechanisms regulating metastatic dormancy are not particularly well understood, however, several hypotheses have been proposed. One hypothesis suggests that tumor cell extrinsic factors such as the immune system actively and purposefully constrain growth of disseminated cells. 13, 14 Another model suggests that a relative inability of disseminated tumor cells to recruit new blood vessels limits frank outgrowth of disseminated disease. 15 Finally, some authors have proposed that metastatic tumor cells simply growth arrest in these new stromal microenvironments due to a relative mismatch between cell-cell and cell-extracellular matrix interactions. 16, 17 Despite differences in the primary mechanism enforcing dormancy, these models are similar in that they hypothesize that disseminated tumor cells must overcome some barrier(s) before progression to a macrometastatic lesion. Metastatic dormancy and subsequent reactivation of growth in melanoma have been recently reviewed. 12, 16, 18 The seed-and-soil hypothesis of cancer metastasis underscores the additional spatial complexity of metastasis. Seed-and-soil posits that patterns of metastasis observed in human cancers result from inherent compatibilities (or incompatibilities) between different tumor cell types and different sites of metastasis. uveal melanoma will have metastatic disease in the liver, which is often the only site of metastasis. 20 In cutaneous melanomas, this principle is also important with common sites of clinically detectable visceral metastasis including: lung, brain, liver and bone, while metastases to other sites are either less common or rarely encountered clinically. 3 Even among common sites of melanoma metastasis, certain epidemiologic patterns suggest additional biological complexity. For example, liver metastasis and brain metastasis are inversely correlated. 3 Our current understanding of the molecular mechanisms underlying melanoma metastasis to different organs has been recently reviewed. 21 PREMALIGNANT DISSEMINATION AND PARALLEL PROGRESSION In traditional models of metastasis, spread to spatially restricted sites is thought to be a unique feature of a subset of particularly aggressive tumor cells that arise late in the course of disease. However, some observations in melanoma and other cancers argue that spread of tumor cells can occur much earlier during primary tumor formation. For example, kinetic models of uveal melanoma based on tumor doubling times estimate that on average, metastatic spread of tumor cells to the liver is initiated up to 5 years before identification and removal of the primary tumor. 22 Genetically engineered mouse models (GEMMs) of epithelial cancers have even demonstrated that spread of abnormal cells can precede primary tumor formation. 23, 24 These disseminated epithelial cells are capable of persisting and subsequently transforming to overt metastatic growths at these distant sites. 23, 25 In this context, it is notable that 4-12% of patients with metastatic melanoma do not have a clinically identifiable primary tumor. [26] [27] [28] There are different explanations for this observation, though one is that some of these metastatic lesions represent malignant progression of abnormal melanocytes that had spread previously.
In fact, non-malignant melanocytes are routinely visualized outside of their normal epidermal location in humans. In compound melanocytic nevi, benign proliferations of melanocytes are found within the dermis, demonstrating that spread through the basement membrane is not a unique feature of malignant cells. Melanocytes can even be visualized in a subset of lymph nodes from normal, non-melanoma bearing patients. [29] [30] [31] [32] These melanocyte clusters in normal lymph nodes are referred to as nodal nevi. Interestingly, many nodal nevi bear BRAF V600E -activating mutations. 33 BRAF V600E mutations are also found in most benign cutaneous melanocytic nevi (mutations in melanoma are discussed in more detail below), 34 leading some authors to speculate that nodal nevi could represent cells that have spread from these benign lesions. 35 However, it is very difficult to definitely exclude the possibility that nodal melanocytes are instead remnants of embryonic development, or embryonic rests. Figure 1 . Melanoma formation and progression. Melanoma formation and metastasis are complex processes. Primary tumor formation has classically been depicted using a linear model in which normal melanocytes progress through several precursor lesions and ultimately to melanoma (individual steps colored in blue). However, substantial evidence suggests that such linear progression is only one pathway to malignancy and that not all steps always occur during progression of individual melanomas. Other pathways to primary tumor formation are also depicted (non-linear). There is additional evidence to suggest that dissemination of cells away from the primary lesion may not be a unique feature of invasive melanomas. The possibility of spread from these lesions is depicted with question marks. Approximately 4-12% of metastatic lesions are not associated with a primary cutaneous melanoma (depicted in orange). The individual steps in metastasis are depicted in green. Unlike primary tumor formation, steps in metastasis are likely to always occur in a linear fashion; although it is unclear whether passage of tumor cells through lymphatics is absolutely required for systemic dissemination. Direct entry of tumor cells into venous return may also be possible and is depicted with a question mark. The transition from micrometastasis to macrometastasis is likely a critical, rate-limiting step in the pathogenesis of many disseminated melanocytic lesions. This transition may take months to years (if it occurs at all) and is preceded by metastatic dormancy. Macroscopic metastatic lesions are thought to be able to seed additional metastases (21 spread). It is unclear whether 21 spread can also occur from micrometastatic lesions, which is depicted with a question mark.
Accordingly, direct evidence supporting early dissemination of metastatic cells in melanoma is currently absent.
The hypothesis that disseminated precancerous or even frankly malignant cells can persist at distant sites and retain the potential to progress to clinically relevant metastatic disease is often referred to as the parallel progression model of metastasis. 36, 37 The parallel progression model has significant conceptual overlap with metastatic dormancy. In this model, continued genetic and/or epigenetic evolution of tumor cells at distant sites facilitates progression to overt metastasis. A prediction of the parallel progression model is that DNA sequence and/or epigenetic modifications should be relatively disparate between primary and metastatic lesions if continued evolution at distant sites is required for progression to overt metastasis. Recent efforts comparing DNA sequence between matched primary and metastatic tumors in a handful of melanoma patients have shown both a relative homogeneity 38, 39 and a relative heterogeneity 40 between matched lesions. Similar studies in epithelial cancers have more commonly reported relative homogeneity between matched primary and metastatic lesions, but significant heterogeneity in DNA sequence has also been reported. 41 These observations suggest that relatively early dissemination with parallel progression and relatively late dissemination with limited evolution at distant sites are both pathways with the potential to give rise to clinically meaningful metastatic disease. However, as it is not clear if-and/or which-of these additional genetic changes have a functionally important role in driving disease progression, these conclusions based on sequencing data are still fairly speculative. The degree to which early dissemination and parallel progression contribute to metastatic melanoma pathogenesis on a population scale remains to be seen.
DIFFERENTIATION IN METASTASIS
The degree and type of differentiation of tumor cells with respect to their ability to metastasize is perhaps the most well-studied relationship in metastasis research. Epithelial-mesenchymal transition is a model of metastasis developed in the study of epithelial cancers, which posits that relative loss of epithelial differentiation and relative gain of mesenchymal characteristics facilitates early steps in metastasis, such as local tissue invasion and intravasation. 42 Despite being a widely accepted paradigm for cancer metastasis, epithelial-mesenchymal transition is not without controversy, even within epithelial cancers. 43 Although melanocytes share some features of differentiated epithelial cells, they are derived from the neural crest and have a differentiation program related to pigment production, 44 suggesting that the relationship between differentiation and metastasis in melanoma may be even more complex.
In melanocytes, differentiation is largely controlled by microphthalmia-associated transcription factor (MITF) and WNT/ b-catenin signaling. MITF is a transcription factor central to melanocyte survival, proliferation and melanin-pigment production. 45 Canonical WNT signaling through b-catenin also promotes increased melanocytic differentiation through direct transcriptional upregulation of MITF. 46 b-catenin is also required for melanocyte survival 47 and differentiated melanocyte function. 48 Both MITF and b-catenin signaling are dysregulated in human melanomas. MITF is amplified in 10% of primary melanomas and 21% of metastases. 49 Germline MITF mutations that alter MITF function are associated with an increased lifetime risk of melanoma. 50, 51 Oncogenic b-catenin mutations are found in B5-7% of melanomas and are thought to lead to constitutive activation of the canonical WNT pathway. [52] [53] [54] [55] More broadly, WNT/b-catenin pathway activation can occur through a variety of mechanisms in addition to mutation of b-catenin, 56 with evidence of pathway activation in at least 1/3 of melanomas. 57 Although the prevalence of MITF and b-catenin dysregulation in melanoma is clear, the effect of this dysregulation with respect to melanoma progression and metastasis is debated. Increased MITF levels and/or levels of melanocytic differentiation antigens in human melanomas have been associated with both a relatively good outcome 58, 59 and a relatively poor outcome. [60] [61] [62] Similarly, attempts to correlate b-catenin levels with outcome have been challenging to interpret. Most consistently, increased b-catenin has been associated with an improved outcome in some larger studies, particularly when combined with additional markers into prognostic models. [63] [64] [65] Some smaller, previously published reports did not find this relationship between increased b-catenin levels and poor outcome and some suggested, rather, that b-catenin dysregulation is associated with disease progression and metastasis. 52, 66, 67 Of course, correlating patient outcome with protein levels or staining patterns is difficult to interpret at a mechanistic level. b-catenin is thought to have different functions depending on its subcellular localization, so levels in tissue likely do not accurately represent functional activity. Finally, prognosis is complex and represents several aspects of disease biology, not only the likelihood of metastasis.
Unfortunately, studies designed to functionally evaluate the roles of MITF and b-catenin in melanoma progression have also been difficult to interpret as a whole. 68 For example, increased levels of MITF have been shown to both increase 69, 70 and decrease [71] [72] [73] [74] metastasis and/or surrogate measures of metastasis in experimental models of melanoma. Similarly, seemingly contradictory results are found with respect to the consequences of increased b-catenin in melanoma progression, with some studies describing a pro-progression role for b-catenin and others describing a progression restricting role. [75] [76] [77] [78] In an attempt to reconcile these observations, several hypotheses have been proposed. Some groups have suggested that a relative balance in the degree of melanocytic differentiation is important in driving metastasis, where both too much or too little can restrict progression. 75, 79 A separate hypothesis, the phenotypic plasticity (or phenotype switching) model, proposes that transient changes in the degree of melanocytic differentiation in a particular melanoma may help to facilitate the different steps of metastasis for which they are advantageous. [80] [81] [82] In this model, increased melanocytic differentiation is thought to drive local proliferation, while relative loss of melanocytic differentiation is thought to facilitate the metastatic spread itself. This model is somewhat consistent with recent studies in epithelial cancers that suggest different cellular programs drive the distinct processes of tumor cell spread and tumor cell proliferation at distant sites. 83, 84 Other groups, including ours, have suggested instead that increased melanocytic differentiation has context-specific effects with respect to progression and metastasis. A recent study by Gallagher et al. 85 suggested that while b-catenin activation in melanocytes restricts cellular motility and migration, b-catenin activation in melanomas enhances metastasis when measured in vivo in a GEMM. Data from additional melanoma GEMMs developed in our lab also suggests that the effects of b-catenin and Mitf may be context-dependent. 86 In these GEMMs, the effect of increased melanocytic differentiation on metastasis was dependent on concurrent genetic changes within the tumor. For example, in GEMMs with mutant Braf and inactivated Pten, b-catenin substantially increased metastasis to the lungs, while in other GEMMs with wild-type Pten, b-catenin seemed to promote local tumor growth, but not metastasis. 86 A last example of the additional layers of complexity in discerning the effect of b-catenin in melanoma progression is illustrated by the recent observation that b-catenin in melanoma cells has substantial immunosuppressive effects in the local tumor microenvironment. 87 Assays that study melanoma metastasis, in for example, an immunodeficient mouse model may not account for these potential tumor-extrinsic effects of b-catenin activation.
Context is of critical importance when studying metastasis in mouse models whether it is genetic background of the tumor, immune status of the host or another variable. A variety of approaches and mouse model systems have been employed, many of which are summarized in Figure 2 . Importantly, these approaches do not study metastasis in a broadly comparable way, an additional consideration that must be taken into account when interpreting experimental data regarding metastasis. Context is also of critical importance when interpreting staining patterns in human melanomas. Staining patterns for a particular protein in primary versus metastatic, treated versus untreated or PTEN wildtype versus PTEN mutant melanomas, for example, may not be broadly comparable. MITF and b-catenin in melanoma serve as an important example of these context-specific considerations in the study of metastasis. Mouse models and the particular advantages of GEMMs will be discussed further below.
TUMOR MICROENVIRONMENT AND MACROENVIRONMENT
during different steps in progression and metastasis and can both inhibit and facilitate progression. 16, 17, 41, 88 In melanoma, changes in the tumor microenvironment can have very powerful effects on tumor cells. For example, embryonic and skeletal muscle microenvironments can restrict both proliferative and metastatic phenotypes. 89, 90 In mouse models of melanoma metastasis, the microenvironment at distant sites is thought to be critical in eliminating disseminated tumor cells and preventing both formation of micrometastases, as well as progression of micrometastases to macrometastases. 91 Interestingly, the microenvironment can also positively influence tumor progression. In epithelial cancers, for example, loss of the transforming growth factor-bII receptor in stromal fibroblasts can initiate neoplasia in otherwise unmodified epithelial cells. 92 Immune cells are one particularly well-studied component of the tumor microenvironment in both melanoma and other cancers. Although the effects of the immune system in melanoma will not be reviewed in detail here, in general, adaptive immunity is thought to help constrain progression of both primary and metastatic disease. 14, 93 Components of the innate immune system such as macrophages, on the other hand, have been shown to facilitate both primary tumor progression and metastasis in a Figure 2 . Approaches for studying metastasis in mice. A variety of methods are used to study metastasis in mice, the most common of which are depicted here. Each of these approaches has relative advantages and disadvantages, including which individual steps of metastasis can be studied using the approach. The steps that can be studied using each method are shown as colored boxes. The immune status of the mouse host is also an important consideration. Immunodeficient mouse models do not account for the effect of the immune system on progression, while immunocompetent mouse models do not allow for the use of human melanoma cells. (a) In orthotopic models, melanoma cells are injected directly into the desired site of metastasis (i.e., the brain) leading to formation of a mass. Either human or murine melanoma cells can be injected into an immunodeficient mouse. Only murine melanoma cells can be injected into an immunocompetent mouse, which must be syngeneic (i.e., B16 melanoma cells into a c57bl/6 mouse). , specifically to the melanocytes of mice. Appropriate combinations of genetic changes result in the spontaneous formation of melanomas from endogenous melanocytes in an immunocompetent mouse. GEMMs recapitulate all steps of melanoma pathogenesis; however, study of human melanoma cells is not possible with GEMMs.
variety of experimental assays. 94 In human melanomas, increased macrophage staining is associated with poor outcome. 95 The relationship between the immune system and melanoma metastasis has been recently reviewed. 96 Tumor cell extrinsic factors that act in an organism-wide fashion are also likely to be important in melanoma metastasis. Perhaps the most well-known example of this type of 'macroenvironmental' effect is the premetastatic niche. In this model, soluble tumor-derived factors circulate systemically and can enact complex programs that alter distant tissues in a way that facilitates later metastasis to those sites. 97 Recent work has implicated tumor-derived exosomes containing melanocytic antigens in initiating premetastatic niche formation in melanoma. 98, 99 Other examples of interactions between established, spatially separated malignant lesions through endocrine-like mechanisms have also been described, 100, 101 though the relative importance of these observations in human melanoma metastasis remains unclear. Additional macroenvironmental factors such as systemic inflammation, [102] [103] [104] organismal metabolism, [105] [106] [107] [108] host genetic background [109] [110] [111] and even male gender 112 can all influence the time course of progression and pattern of metastasis. An improved understanding of these macroenvironmental changes and the specific manner in which they affect tumor and tumor microenvironmental biology will be important moving forward.
MUTATIONS AND METASTASIS
Our understanding of the genetic alterations commonly found in human melanomas has advanced significantly over the past several years (Figure 3) . The mitogen-activated protein kinase/ extracellular-signal-regulated kinase pathway is the most commonly mutated pathway in melanoma, with BRAF and NRAS being the most commonly mutated components. 113 Activating mutations to BRAF and NRAS are also found in the majority of benign melanocytic nevi, suggesting that these changes represent relatively early, although not independently sufficient, events in melanomagenesis. Even the earliest genetic changes in primary tumor formation have been postulated to have a functionally important role in metastasis, 114 which is consistent with the observed early dissemination of abnormal cells in epithelial cancer GEMMs discussed above. The hypothesis that early genetic alterations drive many aspects of tumor progression is also consistent with the observation in human melanomas that proliferation rate 115, 116 and thickness 4 of primary tumors are very strongly correlated with the likelihood of metastasis.
Epidemiologic observations from human melanomas suggest that there is no difference in rates of metastasis between BRAF and NRAS mutant melanomas, 117, 118 though both may exhibit higher rates of metastasis than RAS/RAF wild-type melanomas. 119 Interestingly, a recent study suggested that BRAF V600K -driven melanomas may be more metastatic than BRAF V600E -driven melanomas, 120 suggesting that the metastasis promoting effect of NRAS and/or BRAF may be more complex than mutation presence or absence alone.
Functional studies of mutant RAS and RAF have reinforced the role of these proteins in metastasis. For example, melanoma GEMMs have shown that NRAS mutant melanomas are inherently more metastatic than melanomas driven by other mutant RAS isoforms. 121, 122 In other mouse models, inhibition of mitogenactivated protein kinase/extracellular-signal-regulated kinase signaling can block lung metastasis. 118 Although a specific mechanism by which RAS or RAF mutation drives metastasis in melanoma is unclear, recent studies have proposed mechanisms that relate BRAF mutation to cell invasiveness. 123, 124 The PI3K/AKT pathway is also frequently constitutively activated in melanoma, most commonly through genetic or epigenetic Figure 3 . Recurrent alterations to key signaling pathways in melanoma. Proteins depicted in green are recurrently activated in melanoma. Mechanisms for activation include specific gain-of-function mutations, DNA copy number gains, and/or overexpression. Proteins depicted in blue are recurrently inactivated in melanoma. Mechanisms of inactivation include: point mutations, genomic losses and epigenetic silencing. Proteins depicted in gray are key effectors of pathways that are frequently hyper-activated in melanoma, but are not themselves commonly intrinsically dysregulated. Various negative feedback loops exist within and between pathways, though these are not depicted for simplicity. *Germline MC1R polymorphisms are related to altered pigment production and increased risk of melanoma. **Mutations occur in the TERT promoter rather than in coding DNA sequence.
inactivation of the PTEN tumor suppressor 125, 126 and copy number gains or overexpression of AKT3.
127,128 PTEN has been shown to suppress melanoma metastasis in experimental assays. 129 Melanoma GEMMs support a critical role of Pten loss and subsequent activation of the PI3K/Akt pathway in driving metastasis of melanomas initiated by activating Ras and Raf mutations. 130, 131 In these models, however, activation of PI3K/Akt is also a critical event in primary tumor formation, making specific effects on metastasis difficult to infer. In additional melanoma GEMMs, b-catenin-stabilizing mutations and Lkb1-inactivating mutations have been linked with increased metastasis and are discussed further below.
In the past few years, genome-wide sequencing efforts have identified several new recurrent mutations in melanoma. Some of these mutations include: RAC1, 55,132 PREX2, 55 GRM3,
133

GRIN2A
133 and the TERT promoter. 134 Discerning the functional consequences of these and other recurrent genetic aberrations in melanoma have the potential to uncover additional pathways regulating progression and metastasis (Figure 3 ). For example, PREX family guanine-nucleotide exchange factors have recently been shown to be required for melanoma metastasis in a mouse model. 135 Additional efforts have led to identification of recurrent BAP1 mutations in the majority of metastatic uveal melanomas. 109, 136 Other large scale approaches have been undertaken in an attempt to identify metastasis regulators in melanoma by comparing DNA copy number changes [137] [138] [139] and global mRNA expression between primary and metastatic melanomas. 140 Unfortunately, to date these analyses have had little overlap in genes identified. 140 
RATE-LIMITING STEP IN MELANOMA METASTASIS?
Metastasis is a complicated process with many different steps ( Figure 1 ). Traditionally, metastasis research has focused on early steps in metastasis such as: acquisition of cellular motility, local tissue invasion and intravasation. Conversely, relatively less emphasis has been placed on later steps in metastasis such as: extravasation, survival, and both persistence and proliferation at distant sites. Although these later steps in metastasis are inherently more difficult to study, observations in human melanoma patients suggest that understanding these processes is critical for a comprehensive understanding of the pathogenesis of metastatic melanoma. Early metastasis work in the 1970s, suggested that dissemination of malignant cells from a primary tumor is a fairly common event, with 41 million cells estimated to be shed per gram of tumor per day. 147 In addition to being relatively common, it was also found that circulating tumor cells do not necessarily predict whether metastasis has already or will ever occur. 148 Despite more recent technological improvements in the detection of circulating tumor cells, newer studies still have not consistently found that the presence of circulating tumor cells is related to outcome in melanoma. 149 Further complicating this picture, and consistent with the early dissemination hypothesis, benign melanocytes and nevus cells are routinely detected in the circulation of patients without melanoma. 150, 151 Studies tracking the fate of circulating tumor cells in experimental models of melanoma metastasis suggest that the persistence of disseminated tumor cells at distant sites, the progression of individual tumor cells to micrometastatic clusters of cells and the outgrowth of micrometastasis to clinically relevant macrometastases are relatively rate-limiting events in metastasis pathogenesis. 100, 152 Other studies using a variety of different approaches have also suggested that most disseminated tumor cells never progress to a macroscopic metastasis. 153 Together, these experimental observations begin to shift the focus towards later steps in metastasis.
Patterns of metastasis observed during autopsies of melanoma patients suggest that not all disseminated melanoma leads to clinically relevant metastatic disease. Metastatic tumor distribution is often much more substantial than can be appreciated clinically while patients are alive. For example, intestinal metastasis is detected in only 1-7% of patients clinically, but 26-58% of patients will show evidence of intestinal metastasis at autopsy. 3 Similarly, liver metastasis, while clinically evident in only 10-20% of patients with metastatic melanoma, is found in 54-77% patients at autopsy. 3, 154, 155 In fact, it appears that subclinical melanoma metastases can manifest in almost any part of the body, including sites rarely encountered clinically. 3, 155, 156 More sensitive assays for detecting disseminated tumor cells also suggest that clinically inevident tumor burden may be much higher than can be appreciated in melanoma patients. For example, micrometastatic disease can be detected by reverse transcription-PCR and immunohistochemistry in large proportion of patients and often in lieu of clinically detectable metastatic disease.
Other potential clues that growth at distant sites, rather than simply arriving at distant sites, may be a critical rate-limiting step in the pathogenesis of melanoma metastasis comes from analysis of draining lymph nodes from melanoma patients. The presence or absence of tumor cells in sentinel lymph nodes has important prognostic implications for melanoma patients. 4 However, it has been shown that melanoma patients with histologic evidence of melanoma spread to lymph nodes, but with tumor cell foci o0.1 mm in size, have an equivalent prognosis to patients without any evidence of spread to lymph nodes at all. [158] [159] [160] Interestingly, complete removal of the draining lymph node bed does not improve survival in melanoma patients with evidence of spread. 161, 162 These observations may suggest that the presence of tumor cells in the draining lymph nodes reflects two aspects of tumor biology: (1) the ability to disseminate and persist in distant sites, and (2) the ability to progress to more clinically meaningful lesions at these sites. These additional observations, though certainly somewhat speculative, may help to begin to synthesize newer experimental data with patterns of metastasis in human melanoma patients.
These many considerations emphasize the importance of later steps in metastasis and suggest that progression of clinically undetectable disseminated melanoma to clinically detectable macrometastatic disease may be a particularly important target for continued development of new adjuvant therapeutic approaches. For example, bisphosphonate therapy, a strategy to make bone microenvironments less hospitable to disseminated tumor cells, is now being used in an attempt to eliminate latent micrometastatic disease in the bones of some breast and prostate cancer patients. 163, 164 Analogous, non-conventional adjuvant strategies based on improved understanding of disseminated tumor cell biology may be useful in targeting dormant micrometastatic disease in human melanoma patients.
MOUSE MODELS
Mouse models have been critical in advancing our understanding of metastasis. Mouse models offer the ability to study different steps of cancer metastasis in a relatively physiologic manner. 165 Mice have been employed in a variety of different ways to study metastasis, each with intrinsic advantages and disadvantages ( Figure 2 ). In general, GEMMs are thought to particularly accurately recapitulate the complex biology of tumor initiation, progression and metastasis compared with other in vivo approaches. 166 In melanoma GEMMs, the introduction of genetic changes specifically to endogenous melanocytes of mice results in spontaneous progression of melanocytes to metastatic melanoma in a background that is otherwise unbiased and unmanipulated. [166] [167] [168] Further, GEMMs are not immunocompromised and incorporate potentially critical effects of the immune system in disease progression. Recently developed melanoma GEMMs offer high rates of metastasis and will likely serve as new tools for in-depth study of the mechanisms of metastasis. 86, 169 In the Pten/Braf/b-catenin model developed in our lab, very high rates of spontaneous metastasis occur reproducibly to lymph nodes and lungs. 86 New GEMMs such as the Pten/Braf/b-catenin model offer unique opportunities for the study of metastasis. For example, incorporating fluorescent reporters into these models will allow for an unprecedented ability to visualize and purify cells from various steps of experimentally unmanipulated spontaneous metastasis. Intravital imaging technologies allow real-time visualization of these processes and have been recently reviewed. 170 Processes such as early dissemination of abnormal cells, metastatic dormancy and progression of micrometastatic lesions to frank metastases can be studied and manipulated in these models.
CONCLUSIONS AND FUTURE DIRECTIONS
A fundamental shift is underway in our conceptualization of melanoma metastasis. Although the linear Clark model has been very useful in studying melanoma progression and metastasis, it is becoming clear that this model probably only represents the progression of a subset of melanomas, with many melanomas having more complex and less linear natural histories. As there are many routes to primary tumor formation, there are likely also many routes to the establishment of clinically meaningful metastatic disease. When studying melanoma metastasis, progression may be better visualized as a network rather than a linear series, in which sequential progression through every step represents only one pathway from normal melanocyte to metastatic melanoma (Figure 1) .
Moving forward, it will be important to keep the context of new data regarding melanoma metastasis paramount when interpreting and integrating these observations into existing paradigms. Additionally, incorporating other mediators of tumor biology, such as noncoding RNAs and newer paradigms in tumor biology, such as cancer stem cells, into evolving models of metastasis will be helpful as the role of these entities becomes more clearly defined in melanoma. It is an exciting time in melanoma research in which new tools are helping us to understand disease pathogenesis at a more fundamental level, and new technologies and infrastructure are allowing more rapid translation of these discoveries into novel treatments for melanoma patients.
